The European Consensus Development Conference 2002: Sex steroids and cardiovascular diseases: On the route to combined evidence from OC and HRT/ERT
article
Oral contraceptives (OCs) have a wide spread use and hormonal replacement therapy (HRT) a clear place in the treatment of climacteric symptoms although its long-term use is under continued evaluation. Unbalanced information from the mass media has presented a negative attitude towards the use of female hormones in relation to cardiovascular diseases and the lay public as well as the physician are confronted with negative views whilst their health benefits achieve little, if any, attention. The introduction of OCs has led to socio-economic improvement for both the individual woman and society, which is without precedence in medical history. Consequently there is a need to emphasize beneficial aspects of both OCs and HRT and also to identify and quantify any negative effects and area's of uncertainty to assist clinicians in their decision-making. Chemicals/CAS: dienogest, 65928-58-7; drospirenone, 67392-87-4; elcometrine, 7759-35-5; estradiol, 50-28-2; ethinylestradiol, 57-63-6; glucose, 50-99-7, 84778-64-3; levonorgestrel, 797-63-7; lipid, 66455-18-3; medroxyprogesterone acetate, 71-58-9; nomegestrol acetate, 58652-20-3; progesterone, 57-83-0; trimegestone, 74513-62-5; Contraceptives, Oral; Gonadal Steroid Hormones.
Topics
TNO Identifier
236942
ISSN
03785122
Source
Maturitas, 44(1), pp. 69-82.
Pages
69-82
Files
To receive the publication files, please send an e-mail request to TNO Repository.